Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/11
End: 09/30/12
Due: 09/30/13
Phase: N/A
Priority: Normal
Start: 09/30/10
End: 06/30/11
Due: 06/30/12
Phase: N/A
Priority: Normal
Start: 05/24/18
End: 12/14/19
Due: 12/14/20
Phase: N/A
Priority: Normal
Start: 12/01/15
End: 10/18/19
Due: 10/18/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients | NCT01417780 | Atox Bio Ltd | user2@example.com | None | 2011-12-31 | 2012-09-30 | 2013-09-30 | - | - | 2025-07-14 |
| AB103 Peptide Antagonist in Healthy Volunteers | NCT01166984 | Atox Bio Ltd | user2@example.com | None | 2010-09-30 | 2011-06-30 | 2012-06-30 | - | - | 2025-07-14 |
| Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury | NCT03403751 | Atox Bio Ltd | user2@example.com | None | 2018-05-24 | 2019-12-14 | 2020-12-14 | - | - | 2025-07-14 |
| Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections | NCT02469857 | Atox Bio Ltd | user2@example.com | None | 2015-12-01 | 2019-10-18 | 2020-10-18 | - | - | 2025-07-14 |